Boston Scientific Posts 16% Organic Growth but 27.9% Share Decline
Boston Scientific’s shares have declined 27.9% over six months versus an 11.5% industry drop, pressured by tariff annualization, supply-chain investments and a 3-cent FX EPS headwind for 2026. Despite these challenges, the company achieved 16% organic growth in 2025, surpassing $20 billion in sales with robust Cardiovascular and MedSurg momentum.
1. Stock Performance and Margin Pressures
Over the past six months, Boston Scientific’s shares have fallen 27.9%, underperforming the Medical-Products industry decline of 11.5%. This downturn reflects tariff annualization, ongoing supply-chain investments and a projected 3-cent foreign exchange EPS headwind in 2026 that could temper margin expansion.
2. 2025 Financial Results
In 2025, Boston Scientific delivered 16% organic growth and exceeded $20 billion in sales, with broad momentum across its Cardiovascular and MedSurg segments. Fourth-quarter WATCHMAN growth reached 29%, while its electrophysiology business surged 35% in the quarter and 73% for the year, underpinned by FARAPULSE adoption and expanded mapping capabilities.
3. Growth Drivers and Strategic Deals
APAC and U.S. markets remain key growth engines as the company pursues strategic acquisitions to enhance product adjacencies. The recent closing of the Nalu deal and pending acquisitions of Valencia and Penumbra are expected to diversify its portfolio and strengthen its position in emerging treatment areas.